Search

Search Constraints

You searched for: Author/Creator Charles-Schoeman, Christina

Search Results

1. Abnormal paraoxonase-1 (PON1) enzyme activity in idiopathic inflammatory myopathies. (26th October 2021)

2. Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors. Issue 2 (2nd November 2022)

3. Cholesterol efflux by high density lipoproteins is impaired in patients with active rheumatoid arthritis. Issue 7 (20th January 2012)

4. E064 The relationship between lipid profile changes and inflammation across the Phase 3 sarilumab rheumatoid arthritis (RA) development programme. (12th April 2019)

5. Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs. Issue 7 (14th August 2015)

6. High plasma leptin levels confer increased risk of atherosclerosis in women with systemic lupus erythematosus, and are associated with inflammatory oxidised lipids. Issue 9 (13th June 2011)

8. Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme. Issue 4 (31st January 2023)

9. Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data. Issue 11 (5th August 2020)

10. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. Issue 7 (31st January 2017)